Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
0.5 - 2 μg/mL |
10 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Small Intestine Tissue Lysate(GTX27923) , Human Small Intestine Tissue Slide
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
AATF antibody was raised against a 12 amino acid synthetic peptide from near the carboxy terminus of human AATF.The immunogen is located within the last 50 amino acids of AATF.
Purification
Purified by affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
apoptosis antagonizing transcription factor , BFR2 , CHE-1 , CHE1 , DED
Cellular Localization
Nucleolus
Background
AATF (apoptosis antagonizing transcription factor) was initially discovered as an interaction partner of ZIP kinase (ZIPK) (1), a member of death-associated protein (DAP) kinase family of pro-apoptotic serine/threonine kinases (2). AATF is a phosphoprotein containing an acidic region and a putative leucine zipper domain and nuclear localization signal, features which are typical of transcription factors. AATF inhibits the ZIPK-mediated pro-apoptotic pathway and may activate other anti-apoptotic pathways (3). Recently, it has also been shown to protect neural cells against oxidative damage induced by amyloid b-peptide and to inhibit aberrant production of the b-peptide by interacting with Par-4 (prostate apoptosis response-4), another pro-apoptotic leucine zipper protein that is associated with neuronal degeneration in Alzheimer’s disease (AD) (4,5), suggesting that AATF may have potential therapeutic applications in both familial and sporadic forms of AD.
Database
Research Area